Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study by Roberts, Christine L et al.
Population-based trends in pregnancy
hypertension and pre-eclampsia: an
international comparative study
Christine L Roberts,
1 Jane B Ford,
1 Charles S Algert,
1 Sussie Antonsen,
2
James Chalmers,
3 Sven Cnattingius,
4 Manjusha Gokhale,
5 Milton Kotelchuck,
5
Kari K Melve,
6 Amanda Langridge,
7 Carole Morris,
3 Jonathan M Morris,
1
Natasha Nassar,
1 Jane E Norman,
8 John Norrie,
9 Henrik Toft Sørensen,
2
Robin Walker,
10 Christopher J Weir
11
ABSTRACT
Objective: The objective of this study was to compare
international trends in pre-eclampsia rates and in
overall pregnancy hypertension rates (including
gestational hypertension, pre-eclampsia and
eclampsia).
Design: Population data (from birth and/or hospital
records) on all women giving birth were available from
Australia (two states), Canada (Alberta), Denmark,
Norway, Scotland, Sweden and the USA
(Massachusetts) for a minimum of 6 years from 1997
to 2007. All countries used the 10th revision of the
International Classiﬁcation of Diseases, except
Massachusetts which used the 9th revision. There
were no major changes to the diagnostic criteria or
methods of data collection in any country during the
study period. Population characteristics as well as
rates of pregnancy hypertension and pre-eclampsia
were compared.
Results: Absolute rates varied across the populations
as follows: pregnancy hypertension (3.6% to 9.1%),
pre-eclampsia (1.4% to 4.0%) and early-onset pre-
eclampsia (0.3% to 0.7%). Pregnancy hypertension
and/or pre-eclampsia rates declined over time in most
populations. This was unexpected given that factors
associated with pregnancy hypertension such as pre-
pregnancy obesity and maternal age are generally
increasing. However, there was also a downward shift
in gestational age with fewer pregnancies reaching
40 weeks.
Conclusion: The rate of pregnancy hypertension and
pre-eclampsia decreased in northern Europe and
Australia from 1997 to 2007, but increased in
Massachusetts. The use of a different International
Classiﬁcation of Diseases coding version in
Massachusetts may contribute to the difference in
trend. Elective delivery prior to the due date is the most
likely explanation for the decrease observed in Europe
and Australia. Also, the use of interventions that
reduce the risk of pregnancy hypertension and/or
progression to pre-eclampsia (low-dose aspirin,
calcium supplementation and early delivery for mild
hypertension) may have contributed to the decline.
INTRODUCTION
Hypertension complicates up to 10% of all
pregnancies and is associated with increased
risk of adverse fetal, neonatal and maternal
outcomes, including preterm birth, intrauterine
growth restriction, perinatal death, acute
renal or hepatic failure, antepartum
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ARTICLE SUMMARY
Article focus
- The population prevalence of factors associated
with increased and decreased risk of pregnancy
hypertension and pre-eclampsia has changed
over time, but the impact of these changes is
unknown.
- International comparisons of absolute population
rates of pregnancy hypertension and pre-
eclampsia are hindered by different diagnostic
criteria and methods of data collection.
- Comparing trends between countries overcomes
the difﬁculties in comparing absolute rates.
Key message
- Pregnancy hypertension and/or pre-eclampsia
rates declined over time in northern Europe and
Australia, but not Massachusetts (USA).
- Declining hypertension rates were accompanied
by a downward shift in gestational age with fewer
pregnancies reaching term, the time when the
pregnancy hypertension and pre-eclampsia are
most likely to occur.
Strengths and limitations of this study
- Strengths include numerous validation studies
indicating that the hypertensive disorders are
reliably reported in the population data sets used
for the study and the consistency of trends
across most countries.
- Limitations include a different International
Classiﬁcation of Diseases coding version in
Massachusetts and lack of available information
on clinical interventions.
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Open Access Researchhaemorrhage, postpartum haemorrhage and maternal
death.
1 2 Pregnancy hypertension (also known as preg-
nancy-induced or pregnancy-associated hypertension) has
its onset from 20 weeks of gestation and ranges from
hypertension alone (gestational (non-proteinuric)
hypertension) through proteinuria and multiorgan
dysfunction (pre-eclampsia) to seizures (eclampsia).
3e5
Pre-eclampsia may be superimposed on pre-existing
chronic hypertension. Although pre-eclampsia represents
the severe end of the spectrum, women with any form of
pregnancy hypertension are at increased risk of adverse
outcomes.
67
Risk factors for pregnancy hypertension and pre-
eclampsia have been well documented.
2 7e13 Factors that
increase risk include nulliparity, older maternal age,
multiple births, diabetes, chronic hypertension, obesity,
previous pre-eclampsia, family history of pre-eclampsia,
a new partner and/or $10 years since last pregnancy,
renal disease, and the presence of antiphospholipid
antibodies.
27 e91 11 31 4Decreased risk of pregnancy
hypertension and pre-eclampsia has been associated with
placenta praevia, smoking (although smoking may only
be protective in the non-obese), summer births, low-dose
aspirin and calcium supplementation in high-risk
women, treatment of gestational diabetes and use of
antihypertensive medications.
2 9 10 12 15e19 As the
majority of cases of pregnancy hypertension and pre-
eclampsia occur at term, increasing rates of early elective
delivery may reduce their frequency.
20e23 Trends in
pregnancy hypertension and pre-eclampsia are the result
of the effects of changes in all these factors.
Population rates of pregnancy hypertension (based on
routinely collected data) vary substantially in high-
income countries, ranging from 4% to 10%, including
pre-eclampsia rates of 2% to 5%.
7 11 24e28 At least part
of this variation is likely due to underascertainment
and/or misclassiﬁcation of gestational hypertension and
pre-eclampsia.
29
There are few recent reports of population trends in
pregnancy hypertension.
26e28 International compari-
sons of absolute population rates of pregnancy hyperten-
sion and pre-eclampsia have been considered ‘virtually
impossible’ because of different diagnostic criteria and
methods of data collection.
30 However, comparing trends
between countries overcomes the difﬁculties in
comparing absolute rates. Provided that methods of
reporting do not change from year to year, temporal
variations in each country reﬂect true changes in that
country’s rate of hypertension. The aim of this
study was to determine and compare population-based
trends in pregnancy hypertension and pre-eclampsia in
high-income countries.
METHODS
We used population health data (record-linked birth
and hospital data where available) to determine preg-
nancy hypertension and pre-eclampsia rates in Australia,
Canada, Denmark, Norway, Scotland, Sweden and the
USA. We pre-speciﬁed that (1) participating centres had
to provide a minimum of 6 years of data in the period
from 1997 to 2007, and (2) if coding of hypertension
was based on the International Classiﬁcation of Diseases
(ICD), the same ICD version had to be used for the
entire period. The latter stipulation was made because
pre-eclampsia coding in ICD-9 and ICD-10 are not
comparable.
Study populations and data sources
The study populations included all women who gave
birth (both live births and stillbirths) during the study
period. Eight collaborating centres provided population
health data on a regional or national basis, including:
Australia (the states of New South Wales (NSW) and
Western Australia (WA)), Canada (province of Alberta);
Denmark, Norway, Scotland, Sweden and the USA (state
of Massachusetts). Table 1 provides the average popula-
tion, number of births and information on the data
sources in the eight study areas. The two Australian states
account for approximately 43% of Australian births and
together are referred to as ‘Australia’ in this paper. With
the exception of the USA, all participating countries
have universal health coverage for maternity care
provided by midwives, general practitioners and obste-
tricians. Australia also has a parallel private healthcare
system similar to that in the USA; about one-third of
women seek private obstetric care.
Population health data were obtained from birth and/
or hospital records in each study area. Birth data
including information on maternal characteristics,
pregnancy, labour, delivery and infant outcomes were
collected by the attending midwife or doctor in a stan-
dard format. In Scotland, clinical coding staff within
each hospital’s medical records department extracted
the birth data from all available medical records.
Hospital data included demographic, administrative and
clinical data for all hospital discharges. Diagnoses and
procedures for each admission were coded from the
medical records according to the ICD. The number of
diagnosis ﬁelds available in each medical record varied
by study area, ranging from 6 to 25 (table 1). However,
a consistent number of ﬁelds were used within each
country over the time period of the study.
Record-linked birth and hospital data were utilised in
Australia, Denmark and Massachusetts. In Denmark, the
availability of a unique identiﬁer allows unambiguous,
deterministic linkage of records for each woman. In
Australia and Massachusetts, unique identiﬁers are not
available for record linkage. Consequently, probabilistic
linkage methods were utilised. This involves a complex
process of blocking and matching combinations of
selected variables (such as name, date of birth, address
and hospital) using record-linkage software.
31 Probability
weights are calculated, adjusted for incomplete and
missing data, and used to determine correct matches. The
validity of the probabilistic record linkage is extremely
high, with less than 1% of records having an incorrect
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31e34 Once linked, and prior to release for analysis,
records are stripped of identifying information.
Primary outcomes: pregnancy hypertension and
pre-eclampsia
Population health data from each collaborating centre
were used to estimate the overall incidence of any
pregnancy hypertension (gestational hypertension, pre-
eclampsia or eclampsia) and pre-eclampsia. During
the study period, gestational hypertension was deﬁned
as the de novo onset of hypertension (systolic blood
pressure $140 mm Hg and/or diastolic blood pressure
$90 mm Hg) from 20 weeks’ gestation onwards and
pre-eclampsia as the de novo onset of hypertension
from 20 weeks’ gestation onwards accompanied by
proteinuria.
3
Information on maternal hypertension status was
available from birth and/or hospital data (table 1). In
the birth data, gestational hypertension, pre-eclampsia
(in some cases by severity) and eclampsia data were
generally collected as check-box ﬁelds and/or free text
ﬁelds that were coded according to the ICD. In all
hospital data, hypertension (as diagnosed by the
attending clinician) was coded from the medical record
according to the ICD. Because of expected variations in
reporting and/or coding, we made an a priori decision
that the optimal identiﬁcation of pregnancy hyperten-
sion and pre-eclampsia would be based on local knowl-
edge of reporting methods and validation studies of
hypertension reporting. We aimed to achieve the best
and most consistent reporting in each study area. Since
our focus was on trends over time, our key concern was
to ensure that data collection and reporting within each
study area were consistent over the study period. It was
clear that differences in the baseline rates between study
areas would be unavoidable.
Validation studies focusing on reporting of hyperten-
sive disorders of pregnancy in birth and hospital data
from Europe, North America and Australia have shown
remarkably consistent ﬁndings: pregnancy hypertension
and pre-eclampsia are reliably and accurately reported in
population health data
35; ascertainment is improved
when hypertension is identiﬁed from more than one
data source (birth and hospital records for the birth
admission or birth and antenatal records)
29 36; pre-
eclampsia is generally better ascertained and more
accurately reported than gestational hypertension
24 25 29;
the broad category of ‘any pre-eclampsia’ is more reli-
ably reported than subgroups stratiﬁed by severity
37 38;
similarly the broad category of pregnancy hypertension
is more accurately reported than the subgroups of pre-
eclampsia and gestational hypertension, with the
possible exception of countries where ascertainment of
gestational hypertension is known to be low (including
Denmark and Sweden).
24 29 38 39
Exposures
The collaborating centres provided information on
maternal and pregnancy characteristics of the study
populations including age, parity, smoking at registration
and/or during pregnancy, ethnicity, overweight/obesity
(BMI $25.00 kg/m
2), diabetes, chronic hypertension,
multiple gestation, induction of labour, mode of delivery
and gestational age. Preterm birth (<37 weeks gestation)
was categorised as spontaneous or elective (planned/
elective caesarean section before the onset of labour or
induced labour). Gestational age was reported in
completed weeks, based on the best available estimate
from ultrasound dating and/or menstrual history. The
most reliable source (birth and/or hospital data) was
used to determine exposures.
Approvals
The Publication Board at the Medical Birth Registry of
Norway and the Danish Registry Board approved the
study. In NSW, the record linkage was approved by the
NSW Population and Health Services Research Ethics
Committee (2006-06-011). No other permissions were
required for analysis and presentation of the data.
Statistical analyses
All analyses were based on women who delivered in each
study location. We plotted secular trends in pregnancy
hypertension and pre-eclampsia (per 100 deliveries per
annum) for each study area based on available data over
the study period. Temporal trends in numbers of preg-
nancy hypertension and pre-eclampsia events by study
area were modelled using negative binomial regression.
The covariance matrix was scaled by the deviance
divided by the degrees of freedom and the additional
variance component k estimated by maximum likeli-
hood. Study year was ﬁtted to the models, permitting
estimation of yearly changes (with associated 95% CIs) in
numbers of events relative to baseline. Model ﬁt (p>0.2
in all models) was assessed using the Pearson c
2 good-
ness of ﬁt statistic. Changes over time in population
characteristics were analysed using the c
2 test for trend
with the signiﬁcance level set at p<0.01.
RESULTS
Data were available from the eight study areas for
periods of 6 to 10 years between 1997 and 2007. The
maternity populations ranged in size from an average of
25000 per annum (pa) in Western Australia to 100000
pa in Sweden (table 1). Although not measured from the
same starting time or for the same duration, signiﬁcant
changes in the absolute number of women giving birth
were observed in some areas, with increases in Alberta
(by +26%), Sweden (+17%) and Australia (+7%), and
declines in Scotland (e6%), Denmark (e4%) and
Massachusetts (e4%). In Norway, deliveries declined
from 1999 to 2002 (e6%) and then gradually returned
to baseline in 2006.
Details of maternal and pregnancy characteristics and
trends for each population are presented in table 2,
highlighting some differences between study areas. The
proportion of women delivering their ﬁrst baby ranged
from 40.7% in Norway to 45.2% in Scotland, and
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International trends in pre-eclampsiaincreased in all populations. Multiple gestation rates
were higher in Massachusetts, which also had the highest
proportion of mothers aged $35 years. The Nordic
countries (Denmark, Norway and Sweden) had lower
rates of deliveries among teenagers, comparatively low
rates of medical induction and operative deliveries
(vaginal instrumental and caesarean deliveries), and
lower rates of preterm birth. Maternal age increased over
time in the Nordic countries, Australia and Scotland.
Smoking declined, and inductions and caesarean
sections increased in most study areas. Where data were
available, there was a downward shift in gestational age at
term with an increasing proportion of infants born at
37e39 weeks. This was accompanied by an increase in
preterm births in NSW and Denmark. Information on
the proportion of women who were overweight or obese
was only available in Sweden (35.5%) and Denmark
(32.1%). In Sweden, BMI information was available for
86% of women, and in Denmark data were available for
92% of women for 2004e2006, with no signiﬁcant
change in the rate of overweight or obesity during that
period.
As anticipated, the reported rates of pregnancy
hypertension (3.6% to 9.1%), pre-eclampsia (1.4% to
4.0%) and early onset pre-eclampsia (0.3% to 0.7%)
varied between study areas. The contribution of pre-
eclampsia to the pregnancy hypertension rate also varied
from 23% in Alberta to 74% in Sweden (median¼41%).
Figure 1 shows the trends in pregnancy hypertension
rates for each study area. The average yearly rate
decreased signiﬁcantly during the study periods in four
of the eight areas. In Scotland, pregnancy hypertension
decreased by e6.2% pa (95% CI e5.2% to e7.3%), in
WA by e4.8% pa (95% CI e4.1% to e5.5%), in NSW by
e4.1% pa (95% CI e3.4% to e4.8%) and in Sweden by
e0.6% pa (95% CI e0.1% to e1.1%). There was no
signiﬁcant change in the rate of pregnancy hypertension
in Alberta (p¼0.43), Denmark (p¼0.23) or Norway
(p¼0.90), while in Massachusetts the rate increased
signiﬁcantly by 2.3% pa (95% CI 1.9% to 2.7%).
Trends in pre-eclampsia (ﬁgure 2) mirrored those of
pregnancy hypertension in most study areas with signif-
icant decreases in NSW (e6.0% pa (95% CI e4.2% to
e7.7%)), Scotland (e3.0% pa (95% CI e0.7% to
e5.2%)), WA (e1.3% pa (95% CI e0.3% to e2.3%))
and Sweden (e1.2% pa (95% CI e0.6% to e1.8%)). A
signiﬁcant increase was observed in Massachusetts (2.4%
pa (95% CI 1.5% to 3.3%)). Norway and Denmark
experienced declines in pre-eclampsia rates (e2.5% pa
(95% CI e1.4% to e3.5%) and e0.7% pa (95% CI
e0.02% to e1.4%), respectively), despite the lack of
signiﬁcant reductions in pregnancy hypertension. In
Alberta, the pre-eclampsia rate increased by 4.4% pa
(95% CI 2.4% to 6.4%), albeit from a very low base rate
of 1.1%. Where data were available, the trends in preg-
nancy hypertension and pre-eclampsia were similar
when analyses were restricted to nulliparous women.
DISCUSSION
Most countries saw a decline in the rates of pregnancy
hypertension and/or pre-eclampsia over time. This was
an unexpected result, since factors thought to be posi-
tively associated with pregnancy hypertension such as
pre-pregnancy overweight and obesity, diabetes, multiple
births, and maternal age are generally recognised as
increasing, while smoking during pregnancy (associated
with reduced rates of pregnancy hypertension) has
decreased. Trends in these factors have been proposed
as possible explanations for the increase in pregnancy
hypertension and pre-eclampsia rates reported for the
entire USA from 1987 to 1998 (although the rates
plateaued from 1999 to 2004).
26 In contrast, a study
from Western New York based on a perinatal database
from 1999 to 2003 reported signiﬁcant declines in both
pregnancy hypertension and pre-eclampsia.
27
As expected, we observed a variation between study
areas in baseline ratesdmore marked for pregnancy
hypertension than for pre-eclampsia. However, for study
areas with declining rates, the rates tended to converge
over time. A signiﬁcant part of the variation in baseline
rates was likely related to differences in study population
inclusion criteria and data-recording methods. Although
the lower gestational age boundary varied by country
(gestational age 20e22 weeks or birth weight 350e500 g
for live births and 20e28 weeks for stillbirths), the
impact was likely to be small as pregnancy hypertension
Figure 1 International trends in pregnancy hypertension.
NSW, New South Wales; WA, Western Australia.
Figure 2 International trends in pre-eclampsia. NSW, New
South Wales; WA, Western Australia.
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International trends in pre-eclampsiaand pre-eclampsia most frequently occur in the third
trimester.
7 27 40 Stillbirth, a complication of pre-
eclampsia, is counted only from 28 weeks onwards in the
Swedish data which may have reduced the country’s
rates. However, the number of stillbirths <28 weeks was
low (<2/1000 births), and the similar hypertension rates
in Denmark (which included stillbirths in earlier weeks)
argue against this as a signiﬁcant explanation for
observed differences in pregnancy hypertension rates. At
the same time, validation studies from Denmark and
Sweden indicated underenumeration of gestational
hypertension compared with pre-eclampsia, which would
explain the high ratio of pre-eclampsia to gestational
hypertension in these countries.
24 25
Variability in the age, parity, chronic disease, smoking
and multiple birth distributions will also inﬂuence the
baseline rates of pregnancy hypertension and pre-
eclampsia.
2 71 2Although data from Australia, the USA
and Canada were from regional populations, these
populations are likely to be more homogenous than the
entire country populations and may be more similar to
the European populations. Furthermore, the regional
populations will have fewer climatic differences than
experienced by entire countries like the USA, Canada
and Australia.
The period of available data is another factor inﬂu-
encing the pregnancy proﬁles. For example, caesarean
section rates tended to be lower in countries reporting
for longer time periods; shorter, more recent periods
have the highest rates. Although national and interna-
tional guidelines deﬁning pre-eclampsia and pregnancy
hypertension were consistent during the study period,
changes to Australian and New Zealand guidelines in
2008 may cause a greater divergence in baseline rates in
the future.
2 34 1The inclusion of non-proteinuric
hypertension with multiorgan disease in the clinical
diagnosis of pre-eclampsia could increase the incidence
of pre-eclampsia by up to 25% but should not affect the
overall rate of pregnancy hypertension.
40
Finally, hospital data in all study areas, except Massa-
chusetts, were coded using the 10th revision of the ICD.
Unlike ICD-9, ICD-10 combines mild pre-eclampsia
with gestational hypertension. While this should not
affect the reported rate of pregnancy hypertension, it
reduces the rate of pre-eclampsia in ICD-10 compared
with ICD-9. The change in NSW from ICD-9 in 1997
to ICD-10 in 1998 coincided with a shift from an
increasing to a decreasing trend in pregnancy hyper-
tension, suggesting that the impact of the ICD version
should not be disregarded. Furthermore, study areas
with the highest rates of pregnancy hypertension
(Australia and Massachusetts) have linked data and
more diagnosis ﬁelds per record, characteristics shown
to increase ascertainment in population data.
29 36
Combinations of all these factors, as well as differences
in the population of pregnant women, are likely
contributors to differences in baseline rates between the
study areas.
Although inconsistencies in diagnostic criteria, study
populations, and temporal, geographic and demo-
graphic factors may explain differences in baseline rates,
they do not explain the observed trends in pregnancy
hypertension and pre-eclampsia. The year-to-year trends
are inﬂuenced by the prevalence of risk factors in the
study populations, prenatal care and therapeutic inter-
ventions. Many recognised risk factors for pregnancy
hypertension and pre-eclampsia increased in all or some
of our study populations during the study period,
including nulliparity, advanced maternal age, diabetes,
chronic hypertension and multiple pregnancy, while
smoking rates (an apparent protective factor) declined
everywhere. Diabetes, chronic hypertension and
multiple pregnancy are associated with a two- to three-
fold increase in risk of pre-eclampsia, but occur infre-
quently.
2 9 Small changes in the prevalence of these
factors are unlikely to have a large impact on pregnancy
hypertension rates in the population. While advanced
maternal age and obesity are more common, the
magnitude of risk is lower (less than double).
29
Although only a few countries could provide informa-
tion on obesity in pregnant women, we assume that this
is increasing in all participating countries, based on
population trends.
Nulliparity provides perhaps the most contrary and
puzzling disparity in pre-eclampsia trends. Nulliparity is
common (42e45%, increasing in most populations) and
has an RR of pre-eclampsia estimated at 2.9 (95% CI 1.3
to 6.6).
9 However, in our study, overall nulliparity rates
did not correlate with the pre-eclampsia rates as
expected. Instead, Scotland had both the lowest pre-
eclampsia rates and the highest nulliparity rate, and
Norway had the highest pre-eclampsia rates and the
lowest nulliparity rate. Furthermore, the trends observed
for all women were also observed among nullipara.
Among multipara, pre-eclampsia in a prior pregnancy
has been associated with a sevenfold increased risk in
a subsequent pregnancy.
9 Although women with pre-
eclampsia are also less likely to have another pregnancy,
this does not explain the lower overall risk of pre-
eclampsia in parous women.
11 Consequently, the impact
of trends in parity on the population rates is complex
and difﬁcult to predict.
Changes in elective delivery (labour induction and
caesarean section) are changing the distribution of
gestational age at or near term. Increasing rates of early
elective delivery before 40 weeks gestation have been
reported internationally.
20 22 23 Almost 90% of preg-
nancy hypertension and over 70% of pre-eclampsia
events occur at term, but fewer pregnancies are reaching
40 weeks or beyond.
72 74 0Increasing rates of planned
delivery of women with gestational hypertension could
also explain why more study areas had decreases in
pre-eclampsia rates.
21 Reducing the median length of
gestation by even a few days could mean that a substan-
tial number of women now deliver before they become
hypertensive. It is also possible that utilisation of
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International trends in pre-eclampsiainterventions that reduce the risk of pregnancy hyper-
tension and/or progression to pre-eclampsia (such as
low-dose aspirin, calcium supplementation and possibly
periconceptional multivitamin use in normal-weight
women) are contributing to the decline in hypertension
rates.
15 18 42 43
A strength of our study is the quality of information
collected from very different health systems. While
variation may occur in reporting, completeness and
validity of data, there were no major changes in data
collection or reporting methods during the study
period. Validation studies of the reporting of hyperten-
sion in pregnancy have been conducted in Australia,
Canada, Denmark, Norway, Sweden and the USA, with
consistent ﬁndings about the reliability of each country’s
ascertainment methods.
24 25 29 37e39 44 This consistency
is important when examining the year-to-year variation.
In conclusion, we found declining rates of pregnancy
hypertension and pre-eclampsia in northern Europe and
Australia,areassuringﬁndinginthecontextofincreasing
maternal age, nulliparity and obesity. However, an
increase in these rates was observed in Massachusetts. It is
unclear whether the different ICD coding version used in
the USA played a role in this ﬁnding. The role of elective
delivery prior to the due date (especially late preterm and
early term) in limiting the period of gestation during
which the pregnancy hypertension and pre-eclampsia
risks are greatest warrants further investigation.
Author afﬁliations:
1Perinatal Research, Kolling Institute of Medical Research, University of
Sydney, Sydney, New South Wales, Australia
2Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus N,
Denmark
3Information Services Division, NHS National Services, Edinburgh, UK
4Department of Medical Epidemiology and Biostatistics, Karolinska Institutet,
Stockholm, Sweden
5Maternal and Child Health Department, Boston University School of Public
Health, Boston, Massachusetts, USA
6Medical Birth Registry of Norway, University of Bergen and the National
Institute of Public Health, Bergen, Norway
7Telethon Institute for Child Health Research, Centre for Child Health Research,
University of Western Australia, Perth, Western Australia, Australia
8Tommys Centre for Maternal and Fetal Health, Queen’s Medical Research
Institute, University of Edinburgh, Edinburgh, UK
9Robertson Centre for Biostatistics, University of Glasgow, Glasgow, UK
10Department of Community Health Sciences, University of Calgary, Alberta,
Canada
11Centre for Population Health Sciences, University of Edinburgh Medical
School, Edinburgh, UK
Acknowledgements Population health data were generously provided by the
Alberta Discharge Abstract Database and Birth Registry of Vital Statistics,
NSW Department of Health, WA Department of Health, the Danish National
Registry of Patients and Medical Birth Registry, the Medical Birth Registry of
Norway, Information Services Division of NHS National Services Scotland,
the Swedish Medical Birth Register and a publiceprivate partnership
between the Boston University School of Public Health, and the
Massachusetts Department of Public Health, through a publiceprivate
partnership between with Boston University School of Public Health and the
Centers for Disease Control and Prevention, USA. We thank the NSW Centre
for Health Record Linkage and the WA Data Linkage System for record
linkage. We are also indebted to S Hernandez-Diaz for introducing the Nordic
members of the collaboration.
Funding The research received no speciﬁc grant from any funding agency in
the public, commercial or not-for-proﬁt sectors. However, CLR was supported
by a NHMRC Senior Research Fellowship (no 457078) and a McKern Travelling
Research Scholarship. JBF was supported by NHMRC Capacity Building
funding (no 573122), and CJW was supported by the Edinburgh MRC Hub for
Trials Methodology Research.
Competing interests None.
Ethics approval NSW Population and Health Services Research Ethics
Committee.
Contributors CLR and JBF conceived the project and developed the idea in
collaboration with JMM, JC, JEN, JN and CJW. All authors contributed to study
design, CLR, JC, SC, MK, KMM, NN, HTS and RW were responsible for data
acquisition, and CSA, SA, SC, MG, KKM, AL, CM, RW and CJW contributed to
the analysis of data. CLR and JBF initially drafted the manuscript, and all
authors were involved in critical revision of the intellectual content. All authors
approved the ﬁnal manuscript.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data available.
REFERENCES
1. Duley L. The global impact of pre-eclampsia and eclampsia. Semin
Perinatol 2009;33:130e7.
2. Steegers EA, von Dadelszen P, Duvekot JJ, et al. Pre-eclampsia.
Lancet 2010;376:631e44.
3. Brown MA, Lindheimer MD, de Swiet M, et al. The classiﬁcation and
diagnosis of the hypertensive disorders of pregnancy: statement from
the International Society for the Study of Hypertension in Pregnancy
(ISSHP). Hypertens Pregnancy 2001;20:IXeXIV.
4. Anon. Report of the National High Blood Pressure Education Program
Working Group on High Blood Pressure in Pregnancy.
Am J Obstet Gynecol 2000;183:S1e22.
5. Brown MA, Hague WM, Higgins J, et al; Australasian Society of the
Study of Hypertension in Pregnancy. The detection, investigation and
management of hypertension in pregnancy: full consensus statement.
Aust N Z J Obstet Gynaecol 2000;40:139e55.
6. Buchbinder A, Sibai BM, Caritis S, et al; National Institute of Child
Health and Human Development Network of MaternaleFetal
Medicine Units. Adverse perinatal outcomes are signiﬁcantly higher in
severe gestational hypertension than in mild pre-eclampsia.
Am J Obstet Gynecol 2002;186:66e71.
7. Roberts CL, Algert CS, Morris JM, et al. Hypertensive disorders in
pregnancy: a population-based study. Med J Aust 2005;182:332e5.
8. Cnattingius S, Reilly M, Pawitan Y, et al. Maternal and fetal genetic
factors account for most of familial aggregation of pre-eclampsia:
a population-based Swedish cohort study. Am J Med Genet A
2004;130A:365e71.
9. Duckitt K, Harrington D. Risk factors for pre-eclampsia at antenatal
booking: systematic review of controlled studies. BMJ 2005;330:565.
10. Faiz AS, Ananth CV. Etiology and risk factors for placenta previa: an
overview and meta-analysis of observational studies. J Matern Fetal
Neonatal Med 2003;13:175e90.
11. Hernandez-Diaz S, Toh S, Cnattingius S. Risk of pre-eclampsia in
ﬁrst and subsequent pregnancies: prospective cohort study. BMJ
2009;338:b2255.
12. Ness RB, Zhang J, Bass D, et al. Interactions between smoking and
weight in pregnancies complicated by pre-eclampsia and small-for-
gestational-age birth. Am J Epidemiol 2008;168:427e33.
13. Saftlas AF, Levine RJ, Klebanoff MA, et al. Abortion, changed
paternity, and risk of pre-eclampsia in nulliparous women.
Am J Epidemiol 2003;157:1108e14.
14. Skjaerven R, Wilcox AJ, Lie RT. The interval between pregnancies
and the risk of pre-eclampsia. N Engl J Med 2002;346:33e8.
15. Askie LM, Duley L, Henderson-Smart DJ, et al. Antiplatelet agents for
prevention of pre-eclampsia: a meta-analysis of individual patient
data. Lancet 2007;369:1791e8.
16. Conde-Agudelo A, Althabe F, Belizan JM, et al. Cigarette smoking
during pregnancy and risk of pre-eclampsia: a systematic review.
Am J Obstet Gynecol 1999;181:1026e35.
17. Crowther CA, Hiller JE, Moss JR, et al; Australian Carbohydrate
Intolerance Study in Pregnant Women (ACHOIS) Trial Group. Effect
of treatment of gestational diabetes mellitus on pregnancy outcomes.
N Engl J Med 2005;352:2477e86.
18. Hofmeyr GJ, Atallah AN, Duley L. Calcium supplementation during
pregnancy for preventing hypertensive disorders and related
problems. Cochrane Database Syst Rev 2006;(3):CD001059.
19. Algert CS, Roberts CL, Shand AW, et al. Seasonal variation in
pregnancy hypertension is correlated with sunlight intensity.
Am J Obstet Gynecol 2010;203:215.e1e5.
8 Roberts CL, Ford JB, Algert CS, et al. BMJ Open 2011;1:e000101. doi:10.1136/bmjopen-2011-000101
International trends in pre-eclampsia20. Joseph KS, Demissie K, Kramer MS. Obstetric intervention, stillbirth,
and preterm birth. Semin Perinatol 2002;26:250e9.
21. Koopmans CM, Bijlenga D, Groen H, et al; HYPITAT study group.
Induction of labour versus expectant monitoring for gestational
hypertension or mild pre-eclampsia after 36 weeks’ gestation
(HYPITAT): a multicentre, open-label randomised controlled trial.
Lancet 2009;374:979e88.
22. MacDorman MF, Declercq E, Zhang J. Obstetrical intervention and
the singleton preterm birth rate in the United States from 1991e2006.
Am J Public Health 2010;100:2241e7.
23. Mealing NM, Roberts CL, Ford JB, et al. Trends in induction of labour,
1998e2007: a population-based study. Aust N Z J Obstet Gynaecol
2009;49:599e605.
24. Klemmensen AK, Olsen SF, Osterdal ML, et al. Validity of
pre-eclampsia-related diagnoses recorded in a national hospital
registry and in a postpartum interview of the women. Am J Epidemiol
2007;166:117e24.
25. Ros HS, Cnattingius S, Lipworth L. Comparison of risk factors for
pre-eclampsia and gestational hypertension in a population-based
cohort study. Am J Epidemiol 1998;147:1062e70.
26. Wallis AB, Saftlas AF, Hsia J, et al. Secular trends in the rates of
pre-eclampsia, eclampsia, and gestational hypertension, United
States, 1987e2004. Am J Hypertens 2008;21:521e6.
27. Lawler J, Osman M, Shelton JA, et al. Population-based analysis of
hypertensive disorders in pregnancy. Hypertens Pregnancy
2007;26:67e76.
28. Walker RL, Hemmelgarn B, Quan H. Incidence of gestational
hypertension in the Calgary Health Region from 1995 to 2004. Can J
Cardiol 2009;25:e284e7.
29. Roberts CL, Bell JC, Ford JB, et al. The accuracy of reporting of the
hypertensive disorders of pregnancy in population health data.
Hypertens Pregnancy 2008;27:285e97.
30. Roberts JM, Pearson G, Cutler J, et al; NHLBI Working Group on
Research on Hypertension During Pregnancy. Summary of the
NHLBI Working Group on Research on Hypertension During
Pregnancy. Hypertension 2003;41:437e45.
31. Me ´ray N, Reitsma JB, Ravelli AC, et al. Probabilistic record
linkage is a valid and transparent tool to combine databases
without a patient identiﬁcation number. J Clin Epidemiol
2007;60:883e91.
32. Centre for Health Record Linkage. CHeReL Quality Assurance
Procedures for Record Linkage: http://www.cherel.org.au/downloads.
html (accessed Mar 2011).
33. Western Australian Data Linkage System. http://www.datalinkage-
wa.org/data-linkage/linkage-process (accessed Mar 2011).
34. Declercq E, Barger M, Cabral HJ, et al. Maternal outcomes
associated with planned primary cesarean births compared with
planned vaginal births. Obstet Gynecol 2007;109:669e77.
35. Lain SJ, Hadﬁeld RM, Raynes-Greenow C, et al. Quality of data in
perinatal population health databases: a systematic review. Med Care
2011. http://journals.lww.com/lww-medicalcare/pages/default.aspx
(accepted 31 Jan 2011).
36. Lydon-Rochelle MT, Holt VL, Cardenas V, et al. The reporting of
pre-existing maternal medical conditions and complications of
pregnancy on birth certiﬁcates and in hospital discharge data. Am J
Obstet Gynecol 2005;193:125e34.
37. Geller SE, Ahmed S, Brown ML, et al. International Classiﬁcation
of Diseasesd9th revision coding for pre-eclampsia: how accurate
is it? Am J Obstet Gynecol 2004;190:1629e33; discussion 33e4.
38. Yasmeen S, Romano PS, Schembri ME, et al. Accuracy of obstetric
diagnoses and procedures in hospital discharge data. Am J Obstet
Gynecol 2006;194:992e1001.
39. Joseph KS, Fahey J; Canadian Perinatal Surveillance System.
Validation of perinatal data in the Discharge Abstract Database of the
Canadian Institute for Health Information. Chronic Dis Can
2009;29:96e100.
40. Homer CS, Brown MA, Mangos G, et al. Non-proteinuric pre-
eclampsia: a novel risk indicator in women with gestational
hypertension. J Hypertens 2008;26:295e302.
41. Brown MA, Lowe SA. Current mamangement of pre-eclampsia.
Med J Aust 2009;190:3e4.
42. Bodnar LM, Tang G, Ness RB, et al. Periconceptional multivitamin use
reduces the risk of pre-eclampsia. Am J Epidemiol 2006;164:470e7.
43. Catov JM, Nohr EA, Bodnar LM, et al. association of periconceptional
multivitamin use with reduced risk of pre-eclampsia among normal-
weight women in the Danish National Birth Cohort. Am J Epidemiol
2009;169:1304e11.
44. Vestrheim LC, Austgulen R, Melve KK, et al. Classiﬁcation of pre-
eclamptic pregnancies in health registries. Pregnancy Hypertension
2010;1(S1):54. http://www.pregnancyhypertension.org/.
PAGE fraction trail=8.5
Roberts CL, Ford JB, Algert CS, et al. BMJ Open 2011;1:e000101. doi:10.1136/bmjopen-2011-000101 9
International trends in pre-eclampsia